hematologic malignancies
Genetron Health Licenses ImmuQuad Technology for Blood Cancer Testing
Under the agreement, Genetron gains exclusive rights to develop and commercialize minimal residual disease assays using ImmuQuad's immunogenomics technology.
Germline Variants Contribute to Risk of Developing Aging-Related Clonal Hematopoiesis
Researchers identified one germline variant near TET2 that appears to be specific to individuals of African ancestry.
MSK Clonal Hematopoiesis Clinic Aims to Drive New Strategies for Cancer Risk Assessment, Prevention
Premium
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
Study Spells Out Immune, Genomic, Epigenomic Interactions in Hematological Malignancies
Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.
BioSkryb, St. Jude Expand Licensing Deal for Dx Applications of Single-Cell Tech
BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.